followers 15 popularity
following 19
myunicity is not in any groups


Diabetes and Diabetic Retinopathy Remission and reversal.
SPSINGH | myunicity
The password and username for this plate is available for further development. Please contact the owner.


Apr 14th 2012 at 1:23 PM

*OMEGALIFE-3™ is a natural food supplement and as such is limited from stating medical claims per se. Statements have not been evaluated by the FDA. As such, this product is thus not intended to diagnose, cure, prevent or treat any disease.

Nearly every adult is concerned about maintaining good heart health. Unicity’s Heart Health System features the latest

scientifically formulated supplements for nourishing and strengthening the cardiovascular system.*

Omega-3 Fatty Acid Supplementation.

Fish oil is receiving increasing amounts of media attention as scientific evidence continues to provide proof of potential health benefits, the most notable being the ability to support normal heart function. In fact, the heart-health benefits of fish oil are so compelling, the U.S. Food and Drug Administration stated that, “Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids, (found in fish oil) may reduce the risk of coronary heart disease.” Fish oil has also been shown to maintain a healthy blood pressure. In addition to profound heart-health benefits, fish oil also plays a fundamental role in the development and maintenance of brain and nervous functions such as preservation of memory and mental clarity.*

In 2002 the FDA approved supplementation of DHA in infant formula. Potentially important in fetal and infant neural development, DHA has been shown to be incorporated into brain and retinal cell membranes—particularly during the third trimester and early infant life. Fish oil supports the eyes and helps early development of vision.


DESCRIPTION: OmegaLife-3™ is a blend of omega-3 fatty acids designed to help maintain healthy cardiovascular and cerebral function as well as aiding in the prevention of age-related macular degeneration. OmegaLife-3™ is an amber-colored, semi-viscous, fat-soluble liquid. Each serving of OmegaLife-3™ contains the following active ingredients 800 mg eicosapentaenoic acid (EPA), 400 mg docosahexaenoic acid (DHA), and vitamin E. In addition, it also contains the inactive ingredients gelatin, glycerin, purified water, and orange oil. OmegaLife-3™ has been molecularly distilled to ensure exceptionally pure oil and includes orange oil to prevent a fishy after taste.


BENEFITS AND RESEARCH: Clinical research suggests that fish oil can help support proper brain and visual function. In 2002 the FDA approved supplementation of DHA in infant formula. DHA is poten-tially important in fetal and infant neural development, in that DHA and arachidonic acid have been shown to be in-corporated into brain and retinal cell membranes—particu-larly during the third trimester and early infant life. DHA is the predominant structural fatty acid in the central nervous system and in the retina of the eyes. EPA supports the synthesis of important compounds in the body. EPA is the precursor of thromboxane and leukotriene, compounds involved in supporting healthy circulation. They also promote healthy blood vessels.*

Evidence is accumulating that increasing intakes of EPA and DHA can decrease the risk of cardiovascular disease by preventing arrhythmias, decreasing the risk of thrombosis, decreasing triglyceride levels, slowing the growth of ather-osclerotic plaque, and decreasing inflammation.* The U.S. Food and Drug Administration (FDA) has stated that, “Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may re-duce the risk of coronary heart disease.”

USAGE: Take two softgels per day with food.


SAFETY AND WARNINGS OmegaLife-3™ is well tolerated. Some gastrointestinal discomfort may be experienced as with any dietary sup-plement. Common side effects include a “fishy” taste upon eructation.


HOW SUPPLIED Available in softgels.

REFERENCES Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008 Oct 15:102(8):1040-5 Lee JH, Harris WS, et al. Omega-3 fatty acids for cardiopro-tection. Mayo Clin Proc. 2008 Mar;83(3):324-32. SanGiovanni JP, Chew EY, Sperduto RD, et al. The relation-ship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol. 2008 Sep;126(9): 1274-9. SanGiovanni JP, Parra-Cabrera S, Colditz GA, Berkey CS, Dwyer JT. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to vi-sual resolution acuity in healthy preterm infants. Pediatrics 2000;105:1292-8. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty ac-ids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151-152.

Posted April 14,2012 by SPSINGH



Please to comment

sign in

Remember Me

New to IM faceplate? join free!

Lost Password? click here